Clinical Trial Update: A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a triplet regimen of epcoritamab with lenalidomide and tafasitamab in Diffuse Large B-Cell Lymphoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Epcoritamab (epcoritamab)
• Lenalidomide (lenalidomide)
• tafasitamab (tafasitamab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Lymphoma | Phase 2 | Status: WITHDRAWN